Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carmustine + iodine-125
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Surgical Implant
01
Overview
A combination therapy consisting of carmustine (BCNU) wafers and permanent iodine-125 seed implants used primarily for the treatment of recurrent glioblastoma multiforme (GBM). This approach involves maximal tumor resection followed by implantation of both carmustine wafers and iodine-125 seeds into the tumor cavity. Carmustine works by causing cross-links in DNA and RNA, inhibiting cellular processes, while iodine-125 seeds deliver localized radiation therapy to the tumor site.
02
Targets
DNAGSR (Glutathione reductase)
Beyond the preview
Go deeper on carmustine + iodine-125.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carmustine + iodine-125.